<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561171</url>
  </required_header>
  <id_info>
    <org_study_id>SPP635CRD05</org_study_id>
    <nct_id>NCT00561171</nct_id>
  </id_info>
  <brief_title>Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria</brief_title>
  <official_title>A Phase IIa, Double-Blind, Randomized, Parallel-Design, Four-Week Study to Investigate the Efficacy and Safety of Two Different Doses of the Renin-Inhibitor SPP635 Once Daily in Type II Diabetic Patients With Mild to Moderate Hypertension and Albuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Speedel Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Speedel Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II a, double-blind, randomized, parallel-design, four-week study to
      investigate the efficacy, safety and tolerability of two different doses of SPP635 in type II
      diabetic patients with mild to moderate hypertension and albuminuria.

      The total study duration for patients completing the entire study will be approximately 7
      weeks including a 2 weeks Screening Phase, 1 week Wash-out Phase, 4 week Treatment Phase and
      1 week Follow-up Phase.

      All treatments other than certain antihypertensive drugs (which are to be washed-out) with an
      effect on BP and all antidiabetic treatments must be kept at stable dose during the whole
      study.

      A maximum of 50 patients in total is planned to be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ABPM</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>sitting PB</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hypertension</condition>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lower dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPP635</intervention_name>
    <description>oral once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men or women, 18 to 75 years

          -  hypertension

          -  diabetes mellitus type II

          -  albuminuria

        Exclusion Criteria:

          -  donation of blood in the past month

          -  significant illness

          -  history of malignancy

          -  Heart failure, stroke, myocardial infarction, transient ischaemic attack, or
             hypertensive encephalopathy within the past 6 months

          -  Current or past history of clinically significant electrocardiogram (ECG)
             abnormalities such as permanent 2nd degree atrioventricular (AV) block or higher,
             unstable angina, percutaneous transluminal coronary angioplasty (PTCA), coronary
             artery bypass graft (CABG) or cerebrovascular accident in the last three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Nicolaides, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Speedel Pharma Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. John Barton</name>
      <address>
        <city>Ballinasloe</city>
        <state>Co Galway</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <last_update_submitted>November 20, 2008</last_update_submitted>
  <last_update_submitted_qc>November 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Rolf Schlosshauer / Expert Clinical Manager</name_title>
    <organization>Novartis Pharma AG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

